From:
"Tressie"
Date: 2010-02-21 11:24:52 UTC
Subject: [ferrethealth] Re: Comparison of Meletonin, Lupron, Deslorelin
To: ferrethealth@yahoogroups.com
--- In ferrethealth@yahoogroups.com, "Stephanie" <ferretsandfeline@...>
wrote:
>
...He asked if there was a link or several links where he could get the
vets version of these meds and maybe a comparison of the three. I would
greatly appreciate the info to pass on to him
> Thanks.........Dooks and Wardances
> Stephanie
Hi Stephanie,
There should be information in the FHL archives on this but here are a
few abstracts for your vet:=20
Use of a gonadotropin releasing hormone
agonist implant as an alternative for surgical castration in male
ferrets (Mustela putorius furo) N.J. Schoemaker a,*, R. van Deijk a, B.
Muijlaert a, M.J.L. Kik b, A.M. Kuijten a, F.H. de Jong c, T.E. Trigg
d, C.L.J.J. Kruitwagen e, J.A. Mol a Department of Clinical Sciences of
Companion Animals, Faculty of Veterinary Medicine, Utrecht University,
The Netherlands Department of Pathobiology, Faculty of Veterinary
Medicine, Utrecht University, The Netherlands Department of Internal
Medicine, Erasmus Medical Center, Rotterdam, The Netherlands Peptech
Animal Health, North Ryde, New South Wales 2113, Australia Center of
Biostatistics, Utrecht University, The Netherlands Abstract Surgical
castration in ferrets has been implicated as an etiological factor in
the development of hyperadrenocorticism in this species due to a
castration-related increase in plasma gonadotropins. In search for a
suitable alternative, the effect of treatment with the depot
GnRH-agonist implant, deslorelin, on plasma testosterone concentrations
and concurrent testes size, spermatogenesis, and the typical musky odor
of intact male ferrets was investigated. Twenty-one male ferrets,
equally divided into three groups, were either surgically castrated,
received a slow release deslorelin implant or received a placebo
implant. Plasma FSH and testosterone concentrations, testis size and
spermatogenesis were all suppressed after the use of the deslorelin
implant. The musky odor in the ferrets which had received a deslorelin
implant was less compared to the ferrets which were either surgically
castrated or had received a placebo implant. These results indicate that
the deslorelin implant effectively prevents reproduction and the musky
odor of intact male ferrets and is therefore considered a suitable
alternative for surgical castration in these animals. Copyright 2008
Elsevier Inc. All rights reserved. Keywords: Deslorelin; Gonadotropin;
GnRH; Testosterone; Spermatogenesis=20=20
Deslorelin treatment of
hyperoestrogenism in neutered ferrets (Mustela putorius furo): a case
report A. Prohaczik, M. Kulcsar, Gy. Huszenicza Faculty of Veterinary
Science, Szent Istvan University, Budapest, Hungary ABSTRACT:
Hyperoestrogenism causing progressive alopecia in neutered ferrets may
be induced by ovarian remnant syndrome (ORS) and nodular hyperplasia of
the adrenocortex (hyperadrenocorticism, NHA). The objective of the study
was to determine whether a slow-release implant of a gonadotropin
releasing hormone (GnRH) analogue, deslorelin, has any value in therapy
of hyperoestrogenism of adrenocortical origin (NHA). Three sup- posed
cases of NHA with alopecia and other clinical signs of hyperoestrogenism
(n =3D 2 spayed females in oestrous and n =3D 1 castrated male) were treate=
d
with a subcutaneous implant of 4.7 mg deslorelin acetate. Blood samples
were collected, and plasma levels of estradiol (E2) were determined just
before, and some weeks after treatment. For realistic monitoring, blood
samples for E2 determination were also taken from intact, healthy
(untreated control) females after the beginning of heat (n =3D 5), or
9=9621 days after, with hCG induced ovulation (n =3D 6), or out of
breeding season (n =3D 3). Before treatment, all three alopecic ferrets
showed elevated E2 concentrations (99.45=96139.9 pmol/l) similar to
the untreated control females in oestrous (61.6=96123.02 pmol/l) (P =3D
0.229). Some weeks after the deslorelin administration, the hair of
these ferrets began to grow again and the elevated E2 concentrations
significantly decreased compared to the pre-treatment values (P =3D
0.035). E2 concentrations reached the basal level (12.89=9616.08
pmol/l) typical for that of the untreated control females in anoestrus
or in luteal phase (12.0=9630.58 pmol/l) (P =3D 0.137). All treated
ferrets were examined again 19=9621 months after implant insertion
(the implant still being present) and all of them had normal hair and
were clinically healthy. These observations prove that deslorelin can
suppress the E2 production of NHA, and is therefore a useful tool in the
therapy of hormonal alopecia neutered ferrets. Keywords: deslorelin;
GnRH analogue; estradiol; hyperadrenocorticism=20=20
The Treatment of
Adrenal Cortical Disease in Ferrets with 4.7-mg Deslorelin Acetate
Implants Robert A. Wagner, VMD, Mark R. Finkler, DVM, Kellie A.
Fecteau, PhD, and Tim E. Trigg, PhD Abstract Thirty pet ferrets with
adrenocortical disease (ACD) of varying severity and duration were
evaluated for response to a single administration of a slow release 4.7
mg deslorelin acetate implant. Clinical response to deslorelin was
monitored via a physical examination performed every 3 to 4 months.
Adrenal ultrasound measurements were taken every 3-4 months until
clinical relapse. At clinical relapse, duration of symptom suppression
and adrenal size and growth were determined. Administration of a single
4.7 mg implant of deslorelin acetate resulted in significant decreases
in the clinical signs and hormonal concentrations associated with ACD.
Within 14 days post-implant, vulvar swelling, pruritus, sexual behaviors
and aggression decreased or disappeared. Hair re-growth was evident by
4-6 weeks post implant. Within two months post deslorelin implant,
plasma concentrations of steroid hormones decreased: mean estradiol
concentration decreased 28%; 17 hydroxyprogesterone levels decreased 89%
and androstenedione levels decreased 88%. The response to a single 4.7
mg implant of deslorelin acetate was transitory. The mean SD time to
recurrence of clinical signs was 17.6 5.0 months (range, 8.0-30.0
months). Repeated ultrasound measurements revealed no statistical
difference in size of the adrenals (right or left) before, during the
months of deslorelin implant and at clinical relapse. Slow release 4.7
mg deslorelin implants can effectively be used to temporarily eliminate
the clinical signs and reduce steroid hormone concentrations in ferrets
with ACD. This dose of deslorelin does appear to influence adrenal tumor
growth causing a decrease in adrenal size in some ferrets, and mild
enlargement of adrenal glands in most ferrets with 2 of 30 implanted
animals developing large tumors before clinical relapse. The long-term
effect of treatment with deslorelin on adrenal tumor pathology requires
additional investigation. At this time, surgical removal of the adrenal
tumor remains the only curative treatment; however, 4.7 mg deslorelin
implants are useful in the long-term management of ACD hormone-induced
sequelae and may be as effective assurgical management. Copyright 2009
Elsevier Inc. All rights reserved. Key words: ferret; adrenocortical
disease; adrenal tumor growth; hyperadrenocorticism Tressie
[Non-text portions of this message have been removed]
------------------------------------
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/ferrethealth/
<*> Your email settings:
Individual Email | Traditional
<*> To change settings online go to:
http://groups.yahoo.com/group/ferrethealth/join
(Yahoo! ID required)
<*> To change settings via email:
ferrethealth-digest@yahoogroups.com
ferrethealth-fullfeatured@yahoogroups.com
<*> To unsubscribe from this group, send an email to:
ferrethealth-unsubscribe@yahoogroups.com
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/